Company: STAA
Filing Date: 2025-12-12
Form Type: DFAN14A
Source: 0001213900-25-121255
Chunk: 2

Company: STAAR SURGICAL CO
Filing Date: 2025-12-12
Form: DFAN14A
Chunk 2
---
USE THEY WILL CONTAIN IMPORTANT INFORMATION, INCLUDING ABOUT THE MATTERS TO BE VOTED ON AT THE STOCKHOLDER MEETING AND ADDITIONAL INFORMATION RELATING TO THE PARTICIPANTS AND THEIR DIRECT OR INDIRECT INTERESTS, BY SECURITY HOLDINGS OR OTHERWISE. The definitive proxy statement and an accompanying GREEN Proxy Card will be furnished to some
or all of the Company’s stockholders and will be, along with other relevant documents, available at no charge on the SEC’s
website at https://www.sec.gov/.

Information about the Participants and a description
of their direct or indirect interests, by security holdings or otherwise, is contained on an amendment to Schedule 13D filed by the Participants
with the SEC on November 21, 2025 and is available here.

Exhibit 1

<div align='center'>Broadwood Partners: Leading Proxy Advisory Firm Glass Lewis Reaffirms Recommendation “ AGAINST” STAAR Surgical Sale to Alcon

Contends STAAR’s Process Was Ineffective in Establishing Competitive Auction and Securing Maximum Value for Shareholders

Argues Board’s Procedural Credibility Is “Remarkably Threadbare”

Broadwood Continues to Urge Shareholders to Vote “ AGAINST” Proposed Transaction</div>

NEW YORK – (BUSINESS WIRE) – Broadwood
Partners, L.P. and its affiliates (“Broadwood” or “we”) today announced that Glass, Lewis & Co., LLC (“Glass
Lewis”), a leading independent proxy advisory firm, has reaffirmed its recommendation that shareholders of STAAR Surgical Company
(“STAAR” or the “Company”) (NASDAQ: STAA) should vote “AGAINST” the proposed acquisition
of STAAR by Alcon Inc. (“Alcon”) (NYSE: ALC).

Glass Lewis concluded in its report that “we
do not believe there exists persuasive cause for investors to endorse the revised Alcon arrangement.” The independent
research firm went on to note that “in the absence of, among other alternatives, a full and unambiguous process reset unencumbered
by an existing agreement with a preferred bidder, we maintain deep and foundational reservations regarding this critical [strategic alternatives]
review process administered by the sitting board.”

Neal C. Brasher, Broadwood Founder and President,
said:

“In reaffirming its opposition
to this misbegotten transaction, Glass Lewis correctly concluded that the revised price is not compelling and that the STAAR Board lacks
credibility. Glass Lewis also properly determined that the go-shop process was perform